Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 3:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 4,590 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Crossover Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Glycomacropeptide and Women's Health

NCT05551091
View directory record Official record
Conditions
Obesity
Interventions
glycomacropeptide (GMP)
Dietary Supplement
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
Up to 90 Years · Female only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 3, 2022 · Synced Oct 27, 2026, 3:38 AM EDT
Completed Phase 1Phase 2 Interventional

Acute Nicotine Gum and Tinnitus Loudness in Non-Smoking Adults

NCT07772089
View directory record Official record
Conditions
Tinnitus, Chronic Subjective Tinnitus
Interventions
Nicotine polacrilex gum 4 mg, Placebo gum
Drug · Other
Lead sponsor
San Diego State University
Other
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 27, 2026, 3:38 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study to Assess the Safety and Efficacy of Infliximab to Treat Hidradenitis Suppurtativa

NCT00795574
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
infliximab, Placebo Comparator
Drug
Lead sponsor
Florida Academic Dermatology Centers
Other
Eligibility
16 Years and older
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 24, 2008 · Synced Oct 27, 2026, 3:38 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329

NCT00934089
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
PF-04217329, latanoprost vehicle, latanoprost
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
8
States / cities
Cypress, California • Garden Grove, California • Gardena, California + 4 more
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Oct 27, 2026, 3:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers

NCT02056392
View directory record Official record
Conditions
Solid Tumours
Interventions
Selumetinib, Moxifloxacin, selumetinib placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 9, 2015 · Synced Oct 27, 2026, 3:38 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Placebo-Controlled, Cross-Over Trial of Aripiprazole

NCT00351936
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole, placebo
Drug
Lead sponsor
North Suffolk Mental Health Association
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Oct 27, 2026, 3:38 AM EDT
Completed Phase 2 Interventional Results available

Efficacy of Mesalamine in Diarrhea-predominant Irritable Bowel Syndrome (dIBS)

NCT01327300
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Mesalamine, Placebo
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 12, 2014 · Synced Oct 27, 2026, 3:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single-centre, Randomised, Double-blind, Placebo-controlled, Four Way Crossover Phase I Study to Investigate the Effect on QT/QTc Interval of Ceftazidime NXL104 or Ceftaroline Fosamil NXL104, Compared With Placebo, Using Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers

NCT01290900
View directory record Official record
Conditions
Healthy Male Volunteers
Interventions
NXL104, Ceftaroline, Placebo Infusion, Ceftazidime, Moxifloxacin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2017 · Synced Oct 27, 2026, 3:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of 50 mg Cilostazol Tablets Under Fasting Conditions

NCT00602407
View directory record Official record
Conditions
Intermittent Claudication
Interventions
Cilostazol
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 27, 2026, 3:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Formulation Bridging and Food Effect Study of PBI-200 in Healthy Volunteers

NCT05690932
View directory record Official record
Conditions
Formulation Bridging, Food Effect
Interventions
PBI-200 Tablet, PBI-200 Capsule, PBI-200 Suspension
Drug
Lead sponsor
Pyramid Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Oct 27, 2026, 3:38 AM EDT
Completed Phase 2 Interventional Results available

A Dose-ranging Study to Evaluate Albuterol and Hydrofluoroalkane in Subjects Ages 12 and Older With Persistent Asthma

NCT01058863
View directory record Official record
Conditions
Asthma
Interventions
Albuterol Spiromax®, ProAir® HFA, Placebo Inhaler
Drug · Other
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
13
States / cities
Huntington Beach, California • Rolling Hills Est., California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 27, 2026, 3:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Subjects to Measure the Effects of Food on the Pharmacokinetics of TC-5214

NCT01458899
View directory record Official record
Conditions
Healthy Subjects
Interventions
TC-5214
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2012 · Synced Oct 27, 2026, 3:38 AM EDT
Withdrawn Phase 2 Interventional

The Effect of Sodium Oxybate on Sleep Architecture

NCT00744393
View directory record Official record
Conditions
Mechanically Ventilated ICU Patients
Interventions
sodium oxybate, placebo
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 27, 2026, 3:38 AM EDT
Completed Not applicable Interventional

Effect of Hypoglycemia on Sleep

NCT02687893
View directory record Official record
Conditions
Hypoglycemia
Interventions
Aerobic Exercise, Resistance Exercise
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 45 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Oct 27, 2026, 3:38 AM EDT
Completed Phase 3 Interventional

A Multicenter, Open-Label, Randomized Crossover Trial to Assess Subject Preference for Alprazolam Orally Disintegrating Tablets Compared to Conventional Alprazolam Tablets in Subjects With Anxiety

NCT00139854
View directory record Official record
Conditions
ANXIETY
Interventions
Alprazolam orally disintegrating tablets
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Timeline
2004
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 30, 2013 · Synced Oct 27, 2026, 3:38 AM EDT
Completed Phase 1 Interventional

To Evaluate the Bioavailability of a Tablet of AZD1656

NCT00817505
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
AZD1656
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
20 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2009 · Synced Oct 27, 2026, 3:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 SAD and MAD Study of the Safety, Tolerability and PK of 7HP349 in Normal Healthy Male Subjects

NCT04508179
View directory record Official record
Conditions
Solid Tumor
Interventions
7HP349 Single Ascending Dose, 7HP349 Multiple Ascending Dose, Placebo Single Ascending Dose, Placebo Multiple Ascending Dose, 7HP349 Food Effect
Drug
Lead sponsor
7 Hills Pharma, LLC
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 27, 2026, 3:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Compare Giving AVODART And FLOMAX Together Or In A Combination Capsule In The Fed And Fasted State

NCT00537654
View directory record Official record
Conditions
Prostatic Hyperplasia
Interventions
Treatment sequence A, Treatment sequence B, Treatment sequence C, Treatment sequence D
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
Evansville, Indiana • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Oct 27, 2026, 3:38 AM EDT
Completed Phase 1 Interventional

A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib

NCT00996762
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
lapatinib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
8
States / cities
Scottsdale, Arizona • Tucson, Arizona • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 27, 2026, 3:38 AM EDT
Recruiting Phase 2Phase 3 Interventional

Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM)

NCT07160205
View directory record Official record
Conditions
Idiopathic Inflammatory Myositis (IIM), DERMATOMYOSITIS OR POLYMYOSITIS
Interventions
ULSC (1.5 x 10^8 cells/dose), Placebo (no cells)
Biological
Lead sponsor
Restem, LLC.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Gainesville, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 27, 2026, 3:38 AM EDT
Completed Phase 4 Interventional Results available

A Study of Dex-methylphenidate Extended Release in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00564954
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Dex-methylphenidate hydrochloride extended-release (Focalin XR), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 12 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
5
States / cities
Little Rock, Arkansas • Winter Park, Florida • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2012 · Synced Oct 27, 2026, 3:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of ASEA on Energy Expenditure and Fat Oxidation in Humans

NCT01884727
View directory record Official record
Conditions
Obesity
Interventions
Salt Water, ASEA water
Dietary Supplement
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
50 Years to 65 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 27, 2026, 3:38 AM EDT
Completed Phase 4 Interventional Results available

Tilt-Table Study of the Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension

NCT01518946
View directory record Official record
Conditions
Orthostatic Hypotension
Interventions
Midodrine HCl, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Boca Raton, Florida • New Port Richey, Florida • Lenexa, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 27, 2026, 3:38 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Effects of Ketamine on ERP/EEG Measures in Healthy Volunteers

NCT04928703
View directory record Official record
Conditions
Healthy
Interventions
Ketamine
Drug
Lead sponsor
ERP Biomarker Qualification Consortium
Industry
Eligibility
21 Years to 40 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 27, 2026, 3:38 AM EDT